Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB | P24530 | 16/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | DHPS | P49366 | 1/20 | 0.67 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.67 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9423662 | 1.00 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1029522 | 1.00 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Tert-Butylbenzene SCHEMBL1029521 | 0.89 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7303283 | 0.89 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL9423692 | 0.89 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7305040 | 0.89 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL9423931 | 0.89 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7391382 | 0.89 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7388123 | 0.89 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL9424040 | 0.87 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009747-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OR PREVENTING MUSCLE FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-01-09 | — | — | US | claimed |
| EP-4422634-A2 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OR PREVENTING MUSCLE FIBROSIS | Association Institut de Myologie (FR) | 2024-09-04 | — | — | EP | claimed |
| US-20220265628-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | ENB THERAPEUTICS, INC. | 2022-08-25 | — | — | US | claimed |
| EP-3999062-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | ENB Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| CN-114423425-A | Treatment of urothelial and renal cancers by using endothelin B receptor antagonists | ENB治疗公司 | 2022-04-29 | — | — | CN | claimed |
| US-8173593-B2 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2012-05-08 | — | — | US | claimed |
| US-20090203591-A1 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | ENB THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | ENB THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250009747-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OR PREVENTING MUSCLE FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-01-09 | — | — | US | disclosed |
| US-20240360173-A1 | DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION | ENB THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4422634-A2 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OR PREVENTING MUSCLE FIBROSIS | Association Institut de Myologie (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-12077604-B2 | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation | ENB THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-1906987-A4 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | POPULATION COUNCIL INC (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1906987-A1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | The Population Council, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007012006-A1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | THE POPULATION COUNCIL, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885ABCC3 905/4885 |
| US-12077604-B2 | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation | EDNRB, EDNRA, ESR2 | EDNRA 2/4885EDNRB 1/4885ABCC3 623/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | EDNRA 11/4885EDNRB 8/4885ABCC3 3922/4885 |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885ABCC3 1021/4885 |
| US-20240360173-A1 | DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION | EDNRB, EDNRA, ESR2 | EDNRA 2/4885EDNRB 1/4885ABCC3 623/4885 |
| US-20220265628-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | EDNRB, EDNRA, UTS2R | EDNRA 2/4885EDNRB 1/4885ABCC3 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.